


## Prostate Volume in Sexually Immature and Mature Dogs as Measured by MRI

P. J. McCracken<sup>1</sup>, M. Holahan<sup>1</sup>, S. Born<sup>2</sup>, S. Bellum<sup>2</sup>, N. Gatto<sup>3</sup>, and D. S. Williams<sup>1</sup>

<sup>1</sup>Imaging Department, Merck Research Laboratories, West Point, PA, United States, <sup>2</sup>Toxicological Sciences, Merck Research Laboratories, West Point, PA, United States, <sup>3</sup>Pathology, Merck Research Laboratories, West Point, PA, United States

**Introduction:** Magnetic Resonance Imaging (MRI) techniques have the capability of providing non-invasive and repeatable means of assessing molecular, biochemical, physiological, and anatomical information in laboratory animals and humans with high spatial resolution and high soft-tissue contrast. One area in which MRI may contribute to drug development is augmenting traditional histopathology and complementing histopathological evaluations<sup>1-2</sup>. Among other factors, the addition of longitudinal monitoring has the potential to minimize statistical variability incurring from inter-subject comparisons. Carefully conducted imaging experiments with validation from traditional methods are needed for eventual acceptance of imaging biomarkers by regulatory agencies. *In-vivo* MRI allows for longitudinal monitoring of effects of a compound over a range of dosing regimens and when desired, during a recovery period. MRI also provides a 3D view of the whole organ/tissue under investigation, potentially reducing sampling bias. *In-vivo* prostate volume is an important marker for pre-surgical planning (MRI volume compared with pathology)<sup>3</sup>, beneficial therapeutic effects<sup>4</sup>, or adverse effects. A study was undertaken to evaluate MRI as a non-invasive marker of prostate volume in sexually immature dogs and sexually mature dogs, as well as prostate volume change over 4 weeks.




**Figure 1.** 1.5mm axial slice through prostate (circled in red for volumetric analysis)

compared with MRI findings in an attempt to validate volume measurement results. Results are reported below.

**Results and Discussion:** With excellent capabilities to visualize the prostate (Figure 1), the protocol allowed for a prostate volume coefficient of variation of 0.82% on a single animal scanned three times. This was used to power the study estimating significance to be shown when volume changes exceed 2.3% in a given animal. The MRI findings, based on calculated prostate volumes for animals during the dosing period, were compared for variability, volume change, and ultimately to *ex-vivo* prostate weight at necropsy. Mean and standard error of the mean (SEM) for baseline prostate volumes were  $1.10 \pm 0.13 \text{ cm}^3$  ( $n = 12$ , IM 1 and IM 2) and  $9.36 \pm 0.77 \text{ cm}^3$  ( $n = 12$ , MA 1 and MA 2). There was a significant increase in prostate volume in immature versus mature animals of  $69.42 \pm 27.87\%$  IM 1 and  $-14.00 \pm 7.21\%$  MA 1,  $p = 0.016$ . Results of the 6 animals taken at necropsy are shown in Figure 1, a correlation plot of calculated *in-vivo* prostate volumes versus absolute prostate weights from sexually immature and mature dogs.

**Conclusions:** There was a significant amount of age-related prostate volume change in 4 weeks. The longitudinal variability indicates that age and study duration are important factors if prostate volume is an endpoint of interest. The comparison to *ex-vivo* absolute prostate weights at necropsy shows a high correlation ( $R^2 = 0.916$ ). This demonstrates that Magnetic Resonance Imaging may be used to accurately monitor prostate volume, and therefore weight. With continued validation, future studies might include the addition of MR Spectroscopy or diffusion<sup>5</sup> to better characterize the prostate for drug discovery. The non-invasive nature of the technique could also aid in the reduction in number of animals required for a study and improve power through longitudinal studies.

**References** 1. Beckmann, N. *Brazilian J. Phys.* 2006; v36(1A):16-22. 2. Beckmann *et al.* *Drug Discovery Today.* 2004; v9(1):35-42. 3. Sosna, J. *et al.* *Acad Radiol.* 2003; 10:846-853. 4. Cohen, S.M. *et al.* *Mag Res Med.* 1990; 21, 55-70. 5. Ren *et al.* *Abdom Im* 2008; 1-5.



**Figure 2.** Excellent correlation ( $R^2 = 0.916$ ) between *in-vivo* assessment of prostate volume and *ex-vivo* absolute weight over a range of volumes for sexually immature and sexually mature dogs.